Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» donanemab
donanemab
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
JPM23: Amid launch spree, Eli Lilly expects revenue growth at the 'high end of the industry,' CFO says
Fierce Pharma
Thu, 01/12/23 - 10:27 am
JPMHC 2023
Eli Lilly
pertibrutinib
donanemab
mirikizumab
lebrikizumab
5 FDA decisions to watch in the first quarter
BioPharma Dive
Mon, 01/9/23 - 10:27 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Eli Lilly’s 2023 guidance: Up to 4 new drugs on the way
Medical Marketing and Media
Tue, 12/13/22 - 11:54 pm
Eli Lilly
donanemab
mirikizumab
lebrikizumab
pirtobrutinib
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Thu, 12/1/22 - 07:10 pm
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
Lilly powers through final stretch in critical Alzheimer's race
Fierce Biotech
Tue, 11/1/22 - 07:02 pm
Eli Lilly
Alzheimer's disease
donanemab
lecanemab
Eisai
A Biotech Breakthrough Means Big Gains for These 2 Stocks
Motley Fool
Wed, 09/28/22 - 11:02 am
Eli Lilly
Biogen
Alzheimer's disease
lecanemab
donanemab
With Lilly's Mounjaro set for stardom, an Alzheimer's win would be 'icing on the cake': analysts
Fierce Pharma
Fri, 09/23/22 - 10:48 am
Eli Lilly
type 2 diabetes
obesity
donanemab
Mounjaro
Alzheimer's disease
Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review
BioPharma Dive
Fri, 08/5/22 - 10:59 am
Eli Lilly
Alzheimer's disease
FDA
donanemab
Does Eli Lilly's Future Depend on its Alzheimer's Drug?
Motley Fool
Sat, 04/23/22 - 04:02 pm
Eli Lilly
Alzheimer's disease
donanemab
A trio of amyloid-targeted Alzheimer's drugs will soon see key results, but an analyst predicts only 50-50 odds for one
Endpoints
Wed, 03/9/22 - 11:09 pm
Alzheimer's disease
clinical trials
Roche
Eli Lilly
Biogen
donanemab
lecanemab
gantenerumab
Lilly slows FDA submission of Alzheimer's drug after Medicare decision
BioPharma Dive
Thu, 02/3/22 - 11:43 pm
Eli Lilly
donanemab
Alzheimer's disease
Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm
Fierce Biotech
Fri, 01/21/22 - 11:13 am
Eli Lilly
Biogen
Alzheimer's disease
Aduhelm
donanemab
clinical trials
David Ricks
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Eli Lilly enters strike mode ahead of pivotal Alzheimer's, diabetes launches, CFO says
Fierce Pharma
Mon, 12/20/21 - 11:04 am
Eli Lilly
Alzheimer's disease
diabetes
donanemab
tirzepatide
'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement
Fierce Biotech
Tue, 11/30/21 - 10:25 am
Eli Lilly
donanemab
Alzheimer's disease
Could Eli Lilly Leapfrog Biogen in This Market?
Motley Fool
Wed, 11/17/21 - 10:26 am
Eli Lilly
Biogen
donanemab
Alzheimer's disease
Aduhelm
Eli Lilly kick-starts speedy FDA review for Alzheimer's hopeful donanemab—and a one-on-one test against Aduhelm
Fierce Biotech
Tue, 10/26/21 - 10:50 am
Eli Lilly
Alzheimer's disease
FDA
donanemab
Biogen
Aduhelm
zagotenemab
Biogen pushes for broad CMS coverage of Alzheimer's drug — while Eli Lilly looks to escape an NCD
Endpoints
Wed, 07/28/21 - 10:22 am
CMS
Biogen
Aduhelm
Alzheimer's disease
Eli Lilly
donanemab
Lilly and Banner Alzheimer’s Institute in strategic research collaboration for donanemab trial
Biopharma Reporter
Thu, 07/15/21 - 12:27 pm
Eli Lilly
Banner Alzheimer's Institute
donanemab
clinical trials
Alzheimer's disease
Pages
« first
‹ previous
1
2
3
next ›
last »